Choosing depression treatment in type 2 diabetes: integrating psychiatric efficacy, metabolic effects, and cardiovascular risk. A narrative review
- 1Clinical Laboratory, Ezhou Central Hospital
- 2School of Laboratory Medicine, Hubei University of Chinese Medicine
- 3School of Health and Nursing, Wuchang University of Technology
Abstract
Depression in people with type 2 diabetes (T2D) complicates daily self-management and treatment selection. Psychiatric benefit must be considered alongside weight, glycaemia, cardiovascular tolerability and interactions. This narrative review draws on purposively selected literature and distinguishes direct T2D evidence from mixed-diabetes studies, observational associations and indirect evidence. Study selection and extraction were not consistently duplicated, and no formal de novo risk-of-bias or GRADE assessment was undertaken. A revision-stage qualitative appraisal makes study limitations and population differences explicit. The main T2D pharmacotherapy network comprised 12 short-term trials with 792 participants; its sparse comparisons do not establish a reliable prescribing hierarchy. Individual-agent data suggest clinically relevant differences, but favourable mean HbA1c changes do not establish freedom from hypoglycaemia or hyperglycaemia. Psychological, exercise, digital and collaborative-care interventions also differ in diagnostic eligibility, support intensity and metabolic findings. Cardiovascular tolerability, intermediate safety markers and prevention of clinical events require separate interpretation. Cardiac studies cannot establish T2D-specific cardioprotection. We propose an unvalidated conceptual checklist in which psychiatric urgency precedes cardiometabolic constraints, prior response and patient preferences. Monitoring examples are extrapolated from guidance and pharmacological safety information, not tested T2D-specific schedules. The checklist is intended to structure discussion, not to function as a guideline, validated decision aid or prediction rule.
Related
- Depression, functional disability, and cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome stages 0–3: a nationally representative cohort study
- Polygenic liability for major depression, schizophrenia and bipolar disorder and treatment outcome across major psychiatric disorders
- Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials
- Stage-dependent associations of Cardiovascular-Kidney-Metabolic Syndrome with Cognitive Decline, Depression, and Neuroimaging Signatures in multi-regional older adults
- Impact of a mediterranean diet on metabolic and inflammatory biomarkers in psychiatric patients with metabolic syndrome
BibTeX
@article{tan2026choosing,
title = {{Choosing depression treatment in type 2 diabetes: integrating psychiatric efficacy, metabolic effects, and cardiovascular risk. A narrative review}},
author = {Yanyan Tan and Yuchen Zhang and Lang Yuan and Fei Huang and Yanbin Cheng and Feng Cheng},
journal = {Frontiers in Psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1976656},
url = {https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1976656/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Choosing depression treatment in type 2 diabetes: integrating psychiatric efficacy, metabolic effects, and cardiovascular risk. A narrative review
AU - Yanyan Tan
AU - Yuchen Zhang
AU - Lang Yuan
AU - Fei Huang
AU - Yanbin Cheng
AU - Feng Cheng
PY - 2026
DA - 2026/10/19
JO - Frontiers in Psychiatry
DO - 10.3389/fpsyt.2026.1976656
UR - https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1976656/full
AB - Depression in people with type 2 diabetes (T2D) complicates daily self-management and treatment selection. Psychiatric benefit must be considered alongside weight, glycaemia, cardiovascular tolerability and interactions. This narrative review draws on purposively selected literature and distinguishes direct T2D evidence from mixed-diabetes studies, observational associations and indirect evidence. Study selection and extraction were not consistently duplicated, and no formal de novo risk-of-bias or GRADE assessment was undertaken. A revision-stage qualitative appraisal makes study limitations and population differences explicit. The main T2D pharmacotherapy network comprised 12 short-term trials with 792 participants; its sparse comparisons do not establish a reliable prescribing hierarchy. Individual-agent data suggest clinically relevant differences, but favourable mean HbA1c changes do not establish freedom from hypoglycaemia or hyperglycaemia. Psychological, exercise, digital and collaborative-care interventions also differ in diagnostic eligibility, support intensity and metabolic findings. Cardiovascular tolerability, intermediate safety markers and prevention of clinical events require separate interpretation. Cardiac studies cannot establish T2D-specific cardioprotection. We propose an unvalidated conceptual checklist in which psychiatric urgency precedes cardiometabolic constraints, prior response and patient preferences. Monitoring examples are extrapolated from guidance and pharmacological safety information, not tested T2D-specific schedules. The checklist is intended to structure discussion, not to function as a guideline, validated decision aid or prediction rule.
SN - 1664-0640
ER -